MALAT1 and glioma: For the recent decade, increasing studies have demonstrated the influence of MALAT1 expression on clinicopathological parameters and prognostic outcomes among diffident types of cancer, including digestive cancers [20, 22–26], gliomas [27, 28], estrogen-dependent cancers [29–31], urological cancers [32–34] and other cancers [12, 35].